Journal
JOURNAL OF DRUG TARGETING
Volume 26, Issue 2, Pages 150-161Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1061186X.2017.1350858
Keywords
Brain targeting; selegiline hydrochloride; nasal thermosensitive gel; Parkinson's disease; behavioural studies; biochemical testing
Categories
Funding
- CSIR, New Delhi, India [27(296)/13-EMR-II]
Ask authors/readers for more resources
Selegiline hydrochloride (SL), is an anti-Parkinson's agent, has low-oral bioavailability due to its high first pass metabolism and scarce oral absorption. In the present study, SL mucoadhesive nasal thermosensitive gel (SNT-gel) was prepared to enhance the bioavailability and subsequently, its concentration in the brain. The SNT-gel was prepared using Poloxamer 407-Chitosan combination and optimised formulation was further evaluated for physicochemical parameters. The comparative pharmacodynamic studies including behavioural studies, biochemical testing and histopathology of the brain was carried out in rats for SNT-gel, SL-nasal solution and SL Marketed Tablets. The optimised SNT-gel formulation (SNT-V) revealed sol-gel transition at 33-34 degrees C. In-vitro diffusion study of SNT-V showed 102.37 +/- 2.1% diffusion at 12h which reduced to 89.64 +/- 1.2% in Ex-vivo diffusion. Comparative results of behavioural studies indicated an improved score of photoactometer and reduced motor deficit (catalepsy score) in SNT-gel treatment group as compared with other groups. Similarly, a significant increase in brain dopamine, reduction in monoamine oxidase B level, increase in catalase activity and level of reduced glutathione upon treatment with SNT-gel indicated its effectiveness which was also supported by histopathology results. Therefore, nasal thermosensitive gel holds better potential for brain targeting in Parkinson's disease over the conventional nasal or oral formulations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available